CalciMedica, Inc. (CALC)
NASDAQ: CALC · Real-Time Price · USD
1.450
+0.020 (1.40%)
At close: Jun 27, 2025, 4:00 PM
1.430
-0.020 (-1.38%)
After-hours: Jun 27, 2025, 4:09 PM EDT
Company Description
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage.
The company’s lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
It also develops Auxora for the treatment of acute ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory indications.
The company is based in La Jolla, California.
CalciMedica, Inc.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | A. Leheny |
Contact Details
Address: 505 Coast Boulevard South, Suite 307 La Jolla, California 92037 United States | |
| Phone | 858 952 5500 |
| Website | calcimedica.com |
Stock Details
| Ticker Symbol | CALC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001534133 |
| CUSIP Number | 38942Q202 |
| ISIN Number | US38942Q2021 |
| Employer ID | 45-2120079 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. A. Rachel Leheny Ph.D. | Chief Executive Officer and Director |
| Eric W. Roberts | Chief Business Officer and Vice Chairman of the Board |
| Dr. Sudarshan Hebbar M.D. | Chief Medical Officer |
| Michael J. Dunn B.A., M.B.A. | President and Chief Operating Officer |
| Dr. Anjana Rao Ph.D. | Co-Founder and Scientific Advisor |
| Dr. Patrick Hogan Ph.D. | Co-Founder and Scientific Advisor |
| Dr. Stefan Feske M.D. | Co-Founder and Scientific Advisor |
| Dr. Kenneth A. Stauderman Ph.D. | Co-Founder and Chief Scientific Officer |
| Stephen B. Bardin | Chief Financial Officer |
| John M. Dunn J.D. | General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 27, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jun 27, 2025 | 8-K | Current Report |
| Jun 24, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 9, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 6, 2025 | 8-K | Current Report |
| May 28, 2025 | SCHEDULE 13G | Filing |
| May 14, 2025 | 10-Q | Quarterly Report |
| May 14, 2025 | SCHEDULE 13G/A | Filing |
| May 14, 2025 | 8-K | Current Report |
| Apr 30, 2025 | ARS | Filing |